Finasteride Tablet, Film Coated
Product Images NDC 60687-428

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 60687-428). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100 Ud Carton

Finasteride 5 mg film-coated tablets label from American Health Packaging. The label states 100 tablets (10 x 10) with NDC 60687-428. It includes usage warnings, storage instructions (25° to 30°C), and a note to keep out of reach of children. The label also cautions about pregnancy risks for women and that the drug product is prescription only.*

FDA Label Image

50 Ud Carton

Finasteride 5 mg film-coated tablets label, showing 50 tablets (5 x 10) in oral dosage form. The label includes the NDC number 60687-428-65, states that the product is Rx only, and provides manufacturer details for American Health Packaging. There is a warning that finasteride should not be used by women or children and storage instructions are also noted.*

FDA Label Image

Ahp 428 01 65

Finasteride 5 mg oral film-coated round blue tablet, scored, imprinted with "E" on one side and "61" on the other. The tablet is shown against a black background with both sides visible, matching the product labeled by American Health Packaging under NDC 60687-428.*

FDA Label Image

Blister

Finasteride 5 mg film-coated tablet label from American Health Packaging. The label includes the drug name, strength, dosage form, and manufacturer details. It also displays the NDC number 60687-428 and placeholders for expiration date and lot number, repeated multiple times for strip packaging.*

FDA Label Image

Figure 1

A line graph titled 'Symptom Score in a Long-Term Efficacy and Safety Study' comparing mean change from baseline with standard error bars between placebo and Finasteride groups over four years. Two lines represent placebo (circles) and Finasteride (squares) showing symptom improvement, with Finasteride showing a greater decrease in symptom score.*

FDA Label Image

Figure 2

A line graph titled 'Percent of Patients Having Surgery for BPH, Including TURP,' comparing the percentage of patients over 48 months for Finasteride versus placebo. The y-axis represents percent of patients (0-15%), and the x-axis is observation time in months (0 to 48). The graph shows lower cumulative percent for Finasteride compared to placebo. Below the graph, cumulative number of events and number of patients at risk per year are tabulated for both groups.*

FDA Label Image

Figure 3

A line graph titled 'Percent of Patients Developing Acute Urinary Retention (Spontaneous and Precipitated)' comparing Finasteride and Placebo groups over 48 months. The y-axis shows percent of patients up to 15%, and the x-axis shows observation time in months. Two lines represent Finasteride (lower line) and Placebo (higher line), indicating a lower percentage of acute urinary retention in the Finasteride group. Below the graph, cumulative events and patients at risk per year are tabulated for both groups.*

FDA Label Image

Figure 4

Line graph titled 'Prostate Volume in a Long-Term Efficacy and Safety Study' showing mean percent change from baseline over four years. The graph compares placebo and Finasteride groups, with placebo increasing prostate volume and Finasteride decreasing it over time. Data points and sample sizes for both groups are shown at each year.*

FDA Label Image

Figure 5

A line graph titled 'Cumulative Incidence of a 4-Point Rise in AUA Symptom Score by Treatment Group' displaying percent with event on the y-axis and years from randomization on the x-axis. It compares four treatment groups: Placebo, Finasteride, Doxazosin, and Combination, showing event incidence trends over 0 to 5.5 years.*

FDA Label Image

Structure

Chemical structure of finasteride, showing its characteristic steroid backbone with attached functional groups including a ketone and an amide moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.